Financial Snapshot
Revenues
Revenues
Revenue YoY Change
Revenues
Expenses
Cost Of Revenues
Gross Profit
Gross Profit Margin
Gross Profit
Selling, General & Admin Expense
Research & Development
Depreciation, Depletion & Amortization
SGA Expense to Gross Profit Ratio
R&D To Gross Profit Ratio
DDA To Gross Profit Ratio
Operating Expenses Total
Operating Profits/Loss
Operational Expenses
Interest Expenses
Interest Expenses To Operating Income %
Other Expense/Income
Interest & Other Expense/Income
Income/Loss
Pretax Income
Income Tax
Net Profits/Loss
Pretax Income YoY Change
Income Tax Rate
Net Profits/Loss YoY Change
Basic EPS
Net Income To Revenue Ratio
Pretax & Net Income
Assets & Liabilities
Cash & Short-Term Investments
Cash & Equivalents
Cash To Operating Expenses Ratio
Inventory
Receivables
Total Short-Term Assets
Property, Plant And Equipment
Long-Term Investments
Total Long-Term Assets
Total Assets
Net Income To Total Assets Percentage
Accounts Payable
Short-Term Debt
Long Term Debt Due
Total Short-Term Liabilities
Long-Term Debt
Other Long-Term Liabilities
Total Long-Term Liabilities
Total Liabilities
Short-Term To Long-Term Debt Ratio
Short-Term Assets To Debt Ratio
Long-Term Debt To Net Income Ratio
Assets & Liabilities
Ownership
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares
Stock Issuance & Repurchase
Ownership Data
Return On Shareholders' Equity
Book Value
Free Cash Flow
Free Cash Flow YoY
Free Cash Flow Margin
Dividends
Dividends
Stock Price
About Twist Bioscience Corp
Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. The company is headquartered in South San Francisco, California and currently employs 923 full-time employees. The company went IPO on 2018-10-31. The firm's platform's core is a proprietary technology that develops manufacturing synthetic DNA by writing DNA on a silicon chip. The firm leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. The company has miniaturized traditional chemical DNA synthesis reactions to write over one million short pieces of DNA on each silicon chip. The company offers two product lines: synthetic biology tools and NGS tools, that address different needs of its customers across a variety of applications. The company offers ribonucleic acid and protein products. Its synthetic biology products include synthetic genes and gene fragments, and oligonucleotide or oligo pools.
Industry: Biological Products, (No Diagnostic Substances) Peers: Arcus Biosciences, Inc. EQRx, Inc. ImmunityBio, Inc. FATE THERAPEUTICS INC IVERIC bio, Inc. Prometheus Biosciences, Inc. Sage Therapeutics, Inc. PROKIDNEY CORP. Verve Therapeutics, Inc.
